An update on the treatment of advanced prostate cancer

East African Medical Journal

Volumn 84, Issue 9 SUPPL., 2007, Pages

  Ngugi, P M ^a  

^a UNIVERSITY OF NAIROBI   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN; MALE; PROSTATE TUMOR; REVIEW;

HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 36448953937     PISSN: 0012835X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Marugame T. and Mizuno S. Comparison of Prostate Cancer Mortality in Five Countries: France, Italy, Japan, UK and USA from the WHO Mortality Database (1960-2000).
2. Breslow N., Chan C.W., Dhom G. et al. Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int. J. Cancer. 1977; 20: 680-688.
3. Chinegwundoh F., Enver M., Lee A., et al. Risk and presenting features of prostate cancer amongst African-Caribbean, South Asian and European men in North-east London. BJU Int. 2006; 98:1216-1220.
4. Yawe K.T., Tahir M.B. and Nggada H.A. Prostate cancer in Maiduguri. West Afr. J. Med. 2006; 25: 298-300.
5. Hodges CV. Studies on prostatic cancer. The effect of castration, estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941; 1: 293-297.
6. Vaughan DJ. Hormonal therapy for advanced prostate cancer. Annals Med. 2000; 132: 584-585.
7. Clav C.A., Perera S., Wagner J.M., et al. Physical function in men with prostate cancer on androgen deprivation. Therapy Phys. Ther. 2007.
8. Taichman R.S., Loberg R.D., Mehra R. et al. The evolving biology and treatment of prostate cancer. J. Clin. Invest. 2007; 117: 2351-2361.
9. Katz A. Quality of life for men with prostate cancer. Cancer Nurse. 2007; 30: 302-308.
10. Granfors T., Modia H., Damber J.E. et al. Longterm followup of a randomized study of locally advanced prostate cancer treated with combined orchidectomy and external beam radiotherapy versus radiotherapy alone. J. Urol. 2006; 176: 544-547.
11. Frydenberg M., and Wijesinha S. Diagnosing prostate cancer - what GPs need to know. Aust. Fam. Physician. 2007; 36: 345-347.
12. Hebert J.R., Ghumare S.S., Gupta P.C. et al. Links. Stage at diagnosis and relative differences in breast and prostate cancer incidence in India: comparison with the United States. Asian. Pac. J. Cancer Prev. 2006; 7: 547-555.
13. Futterer J.J. MR imaging in local staging of prostate cancer. Eur. J. Radiol. 2007; 63: 328-334. Epub 2007 Aug 8.
14. Mitterberger M., Pinggera G.M., Pallwein L. et al. The value of three-dimensional transrectal ultrasonography in staging prostate cancer. BJU Int. 2007;100:47-50. Epub 2007; Apr 13.
15. Hricak H., Chovke P.L., Eberhardt S.C. et al. Imaging prostate cancer: a multidisciplinary perspective. Radiology. 2007; 243: 28-53.
16. Akin O. and Hricak H. Imaging of prostate cancer. Radiol. Clin. North Am. 2007; 45: 207-222.
17. Hsu C.Y., Joniau S., Oven R. et al. Transrectal ultrasound in the staging of clinical T3a prostate cancer. Eur. J. Surg. Oncol. 2007; 33: 79-82. Epub 2006 Oct 24.
18. Klatte T., Klatte D., Bohm M., et al. Radionuclide bone scan in patients with newly diagnosed prostate cancer. Clinical aspects and cost analysis. Urologe A. 2006; 45: 1293-1294, 1296-1299.
19. Andrew V. Schally Luteinizing hormone-releasing hormone analogues and hormone ablation for prostate cancer: state of the art. BJU Intern. 2007; 100: (s2), 2-4.
20. Fitzpatrick J.M. Is hormone ablation still the right choice for advanced prostate cancer? BJU Int. 2007; 100 (Suppl 2):36.
21. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000; 355: 1491-1498.
22. Taichman R.S., Loberg R.D., Mehra R. et al. The evolving biology and treatment of prostate cancer. J. Clin Invest. 2007; 117: 2351-2361.
23. Botto H., Rounret M., Mathieu F., et al. Multicentre randomized trial comparing triptorelin medical castration versus surgical castration in the treatment of locally advanced or metastatic prostate cancer. Prog. Urol. 2007; 17: 235-239.
24. De Paula A.A., Piccelii H.R., and Pinto N.P., Economical impact of orchiectomy for advanced prostate cancer. Int. Braz. J. Urol. 2003; 29: 127-130.
25. Usami M., Akaza H., Arai, et al. Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients. Prostate Cancer Prostatic Dis. 2007; 10: 194-201.
26. 1versen P., Johansson J.E., and Lodding P., Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median folio wup from the Scandinavian Prostate Cancer Group Study Number 6. J. Urol. 2004; 172(5 pt 1): 1871-1876.
27. Wirth M., Tyrrell C., Wallace M., et al Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. Urology. 2001; 58: 146-151.
28. Rvan C.J. and Small E.J. Androgen deprivation therapy in locally advanced and metastatic prostate cancr Minerva Urol. Nefrol. 2006; 58: 119-126.
29. J. Urol. 2004; 172(5 Pt 1): 1871-1876.
30. Stein M.E., Boehmer D. and Kuten A. Radiation therapy in prostate cancer. Recent results. Cancer Res. 2007; 175: 179-199.
31. Israeli R.S., Rosenberg S.J., Saltzstein D.R. et al. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin. Genitourin. Cancer. 2007; 5: 271-277.
32. Yuen K.K., Shelley M., Sze W.M., et al. Bisphosphonates for advanced prostate cancer. Cochrane Database Syst Rev. 2006; 18: CD006250.
33. Tanaka T., Kawashima H. Kuratsukuri K. et al. The effect of bisphosphonates on bone metastasis of hormone-refractory prostate cancer. Hinyokika Kiyo. 2006; 52: 491-494.
34. Bertelli G., Heouaine A., Arena G., et al. Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients. Cancer Chemother. Pharmacol. 2006; 57: 46-51.
35. Di Lorenzo G., Autorino R., Figg W., D., et al. Hormone-refractory prostate cancer: where are we going? Drugs. 2007; 67: 1109-1124.
36. Muthuramalingam S.R., Patel K., and Protheroe A. Management of patients with hormone refractory prostate cancer. Clin. Oncol. (R. Coll. Radiol). 2004; 16: 505-516.